I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| oligodendrocyte | 13 studies | 29% ± 12% | |
| pericyte | 7 studies | 19% ± 3% | |
| epithelial cell | 6 studies | 26% ± 9% | |
| endothelial cell | 5 studies | 21% ± 2% | |
| fibroblast | 5 studies | 23% ± 8% | |
| oligodendrocyte precursor cell | 5 studies | 25% ± 7% | |
| non-classical monocyte | 4 studies | 29% ± 10% | |
| smooth muscle cell | 4 studies | 25% ± 7% | |
| abnormal cell | 4 studies | 27% ± 7% | |
| goblet cell | 4 studies | 24% ± 7% | |
| basal cell | 4 studies | 22% ± 4% | |
| CD16-positive, CD56-dim natural killer cell, human | 3 studies | 19% ± 4% | |
| muscle cell | 3 studies | 21% ± 4% | |
| astrocyte | 3 studies | 26% ± 6% | |
| glutamatergic neuron | 3 studies | 29% ± 10% | |
| dendritic cell | 3 studies | 26% ± 6% | |
| plasmacytoid dendritic cell | 3 studies | 18% ± 2% |
